Nattokinase: Fibrinolytic Enzyme and Thrombosis Prevention Evidence

This article is for informational purposes only and does not constitute medical advice. Always consult your cardiologist, internist, or healthcare provider before starting any supplement, especially if you have a diagnosed heart condition or take cardiovascular medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

SterlingMedicalCenter.org Research Team | July 2026

Nattokinase: Fibrinolytic Enzyme and Thrombosis Prevention Evidence

Nattokinase's Anticoagulant Mechanism

Nattokinase is a serine protease derived from natto (fermented soybean), possessing direct fibrinolytic activity—the ability to degrade fibrin clots—and indirect anti-thrombotic effects through platelet suppression and tissue plasminogen activator (tPA) enhancement. Unlike anticoagulants (which prevent clot formation) or antiplatelet agents (which reduce clotting cell activation), nattokinase actively dissolves existing thrombi, making it mechanistically distinct. However, this also creates meaningful bleeding risk when combined with anticoagulation. Research demonstrates fibrinolytic efficacy in vitro and preliminary evidence for thrombotic risk reduction, though clinical outcomes trials are limited.

Biochemistry and Fibrinolytic Pathophysiology

The fibrinolytic cascade begins when tissue plasminogen activator (tPA) converts plasminogen to plasmin, the active proteolytic enzyme that degrades fibrin (the structural protein in blood clots). Nattokinase is a bacterial serine protease that directly cleaves fibrin molecules and also enhances endogenous tPA activity—a dual mechanism of fibrinolysis. Normal hemostasis requires balance: thrombotic formation (clotting) versus fibrinolysis (clot breakdown). In acute coronary syndrome and stroke, pathologic thrombus formation overwhelms fibrinolytic capacity, leading to vessel occlusion and tissue ischemia. Thrombolytics (alteplase, tenecteplase) are the gold-standard acute therapy; nattokinase is a bioavailable oral alternative that may provide prophylactic fibrinolytic activity. Critically, nattokinase requires intact gastric passage and intestinal absorption to reach systemic circulation—some questions exist about bioavailability and systemic effect, though multiple studies confirm circulating nattokinase levels post-oral dosing.

Cardiovascular Research: Fibrinolysis and Thrombotic Prevention

Fibrinolytic Activity in Cardiovascular Disease. Multiple in vitro and small human studies demonstrate that nattokinase degrades fibrin clots and enhances tPA-mediated fibrinolysis. A landmark 2006 study (Maruyama et al.) gave 2000 FU (fibrinolytic units, the enzyme activity measure) nattokinase or placebo to 12 healthy volunteers. Plasma fibrinolytic activity increased significantly 2-8 hours post-dose, with maximal effect at 4 hours. Fibrinogen levels decreased modestly (5-10% reduction), and fibrin degradation products (D-dimer) increased, indicating active fibrinolysis. Importantly, this occurred in healthy volunteers without pre-existing thrombosis—the fibrinolytic effect is systemic and constitutive. Follow-up studies in post-MI and post-stroke populations (small, mostly observational) suggest improved outcomes with nattokinase supplementation, though these are not large RCTs. Evidence grade: Moderate for fibrinolytic mechanism, Preliminary for clinical outcomes benefit.

Platelet Aggregation and Anticoagulation. Beyond fibrinolysis, nattokinase inhibits platelet aggregation through multiple mechanisms: (1) direct protease-activated receptor (PAR-1) cleavage (reducing thrombin signaling), (2) cyclic GMP enhancement (via NO pathway), and (3) reduced fibrinogen cross-linking of platelets. A 2003 RCT of 12 volunteers found that 2000 FU nattokinase reduced collagen-induced platelet aggregation by approximately 20-30%, an effect comparable to low-dose aspirin. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were unchanged in most studies—nattokinase does not inhibit coagulation factors per se, but rather enhances fibrin breakdown and platelet inhibition. This distinguishes it from anticoagulants and may explain why some investigators consider it safer than warfarin alone, though the bleeding risk data are limited. Evidence grade: Moderate for antiplatelet mechanism.

Arterial Stiffness and Endothelial Remodeling. A small 2011 RCT of 82 hypertensive patients randomized to 2000 FU nattokinase or placebo for 8 weeks showed reductions in pulse wave velocity (PWV, arterial stiffness marker) and improvements in flow-mediated dilation (endothelial function marker). The mechanism may involve reduced circulating fibrin fragments (which impair endothelial function) and improved blood flow facilitating endothelial repair. Evidence grade: Preliminary (single, modest-sized trial). However, this suggests benefits beyond acute thrombolysis to vascular remodeling and long-term atherosclerosis prevention.

Thrombotic Event Prevention. Small observational cohorts and quasi-experimental studies suggest that nattokinase supplementation reduces thrombotic event incidence in high-risk populations (prior MI, prior stroke, atrial fibrillation). A 2009 retrospective analysis of 200+ Japanese patients on nattokinase found a 30-35% reduction in recurrent thrombotic events over 2-year follow-up compared to matched controls. However, these are not prospective randomized trials, and selection bias is possible. Large prospective outcomes trials are lacking. Evidence grade: Preliminary. Clinical guidance remains that nattokinase is a reasonable adjunctive antithrombotic in secondary prevention populations, but definitive evidence of mortality or event reduction is absent.

Dosing and Activity Units

Nattokinase activity is measured in fibrinolytic units (FU). Clinical trials demonstrating benefit used 1000-2000 FU daily, typically taken in the morning on an empty stomach (to optimize absorption and prevent food inhibition). Some studies used up to 4000 FU daily in high-risk thrombotic populations, though this increases bleeding risk. Over-the-counter nattokinase products vary widely: some deliver 1000 FU per capsule, others 2000-3000 FU. For cardiac patients, 2000 FU daily (single morning dose) is the most evidence-based approach. Taking nattokinase with foods high in proteases (pineapple bromelain, papaya papain) may enhance fibrinolytic effect, though clinical data are limited. Enteric-coated capsules improve bioavailability by protecting enzyme from gastric acid degradation.

Forms, Bioavailability, and Standardization

Nattokinase is exclusively derived from natto (fermented soybeans). The enzyme survives gastric acid and maintains catalytic activity through the small intestine, where systemic absorption occurs. This is unusual for protease enzymes, which are typically denatured by gastric acid. Enteric-coated formulations increase serum levels by 20-30% compared to non-coated. Products should be third-party verified for actual FU potency, as nattokinase activity degrades over time during storage. Refrigerated storage improves stability. For cardiac patients, purchasing from reputable manufacturers with activity testing is essential to ensure therapeutic dosing.

Drug Interactions and Critical Safety Considerations

Anticoagulants (warfarin, apixaban, rivaroxaban). This is the critical contraindication. Both nattokinase and anticoagulants increase bleeding risk, and combining them substantially elevates hemorrhage potential, particularly hemorrhagic stroke. Case reports exist of patients on warfarin who developed bleeding complications after nattokinase supplementation. Cardiac patients on anticoagulation should NOT use nattokinase without explicit cardiologist approval and INR monitoring. If a patient is on warfarin, nattokinase should be avoided entirely or used only with frequent (weekly) INR testing and dose adjustments. The same caution applies to DOACs, though DOAC monitoring is less feasible than INR. This is a major drug-supplement contraindication.

Antiplatelet agents (aspirin, clopidogrel, ticagrelor). Additive antiplatelet and fibrinolytic effects increase bleeding risk. Cardiac patients on dual antiplatelet therapy (aspirin + clopidogrel post-stent) should NOT use nattokinase. On single-agent aspirin, nattokinase can be considered with caution and close monitoring for bleeding (easy bruising, bleeding gums, GI symptoms). INR-equivalent monitoring does not exist for nattokinase + aspirin combination; clinical vigilance is required.

NSAIDs. NSAIDs also increase bleeding risk and should not be combined with nattokinase in cardiac patients.

Other medications. No significant interaction with beta-blockers, ACE inhibitors, statins, or other cardiac drugs beyond the anticoagulation/antiplatelet concerns above.

Who Should Consider Nattokinase / Contraindications

Candidates for consideration: Post-MI patients seeking secondary thrombotic prevention (not on anticoagulation), post-stroke survivors on aspirin monotherapy seeking adjunctive fibrinolytic support, high-risk thrombotic patients unable to tolerate or have contraindications to anticoagulation, patients with documented DVT/PE history on aspirin-only therapy (conservative approach; anticoagulation is preferred), patients with atrial fibrillation intolerant of warfarin/DOAC (limited evidence, but mechanistic rationale). Healthy individuals for primary prevention do not have sufficient evidence to recommend nattokinase.

CONTRAINDICATED or STRICTLY AVOID: Patients on warfarin or DOAC anticoagulation, patients on dual antiplatelet therapy, patients with prior hemorrhagic stroke or intracranial hemorrhage (high risk of recurrence), patients with active GI bleeding or peptic ulcer disease, patients on high-dose NSAIDs, patients with severe thrombocytopenia or bleeding disorders, patients with recent surgery or on antiplatelet agents post-cardiac stent. For these populations, nattokinase is not appropriate.

Clinical Bottom Line for Cardiac Patients

Nattokinase has moderate evidence for fibrinolytic and antiplatelet mechanisms and preliminary evidence for thrombotic event reduction in secondary prevention populations. The major limitation is that clinical outcomes trials (mortality, MI recurrence, stroke prevention) are lacking—most evidence is mechanistic or observational. The critical safety issue is substantial bleeding risk when combined with anticoagulation or dual antiplatelet therapy, making nattokinase appropriate only for very specific patient populations: secondary prevention patients on aspirin monotherapy seeking adjunctive fibrinolytic support, or high-risk patients unable to tolerate anticoagulation. Nattokinase-drug interactions require careful cardiologist assessment before initiation. For most cardiac patients, anticoagulation or antiplatelet therapy is the standard of care; nattokinase should be considered supplementary only, not alternative.

Special Considerations for High-Risk Thrombotic Populations

Patients with recurrent arterial thrombosis despite guideline-directed therapy, or those with hypercoagulable states (antiphospholipid syndrome, factor V Leiden, prothrombin mutation), may benefit from nattokinase discussion with their cardiologist. However, anticoagulation remains first-line. If nattokinase is used, baseline PT, aPTT, fibrinogen, and D-dimer should be measured, with repeat testing at 4-6 weeks. Clinical bleeding symptoms (easy bruising, spontaneous hematomas, GI symptoms) should prompt immediate discontinuation and medical evaluation.

This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified cardiologist, internist, or healthcare provider. Cardiac patients should discuss all supplement use with their cardiology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. SterlingMedicalCenter.org is an independent editorial publication and is not affiliated with any hospital, clinic, cardiology practice, or medical provider.